uniQure (NASDAQ:QURE) CEO Sells $952,063.12 in Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 21,082 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the transaction, the chief executive officer owned 519,227 shares in the company, valued at $23,448,291.32. The trade was a 3.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of QURE opened at $44.48 on Friday. The stock has a 50 day moving average of $32.51 and a 200 day moving average of $24.43. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of -12.78 and a beta of 0.90. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. As a group, sell-side analysts forecast that uniQure N.V. will post -3.56 earnings per share for the current year.

Institutional Trading of uniQure

Institutional investors have recently modified their holdings of the business. State Street Corp boosted its holdings in uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its holdings in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of uniQure in the fourth quarter worth $33,062,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on QURE. Mizuho raised their price objective on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research note on Tuesday, May 5th. Leerink Partners lifted their price target on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Chardan Capital upped their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.